製品の概要

  • 製品名Anti-MSH2 antibody - ChIP Grade
    MSH2 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to MSH2 - ChIP Grade
  • アプリケーション適用あり: WB, IHC-Fr, IP, IHC-P, ChIPmore details
  • 種交差性
    交差種: Mouse, Human
  • 免疫原

    Full length recombinant MSH2 protein.

  • ポジティブ・コントロール
    • HCT116 OR SW480 cells

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab16833 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 100 kDa.
IHC-Fr Use a concentration of 2 µg/ml.
IP Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration.
ChIP Use at an assay dependent concentration. PubMed: 22941650

ターゲット情報

  • 機能Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.
  • 組織特異性Ubiquitously expressed.
  • 関連疾患Defects in MSH2 are the cause of hereditary non-polyposis colorectal cancer type 1 (HNPCC1) [MIM:120435]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. MSH2 mutations may predispose to hematological malignancies and multiple cafe-au-lait spots.
    Defects in MSH2 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
    Defects in MSH2 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
    Defects in MSH2 are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.
  • 配列類似性Belongs to the DNA mismatch repair mutS family.
  • 翻訳後修飾Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.
    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • 細胞内局在Nucleus.
  • Information by UniProt
  • 参照データベース
  • 別名
    • BAT26 antibody
    • COCA 1 antibody
    • COCA1 antibody
    • DNA mismatch repair protein Msh2 antibody
    • FCC 1 antibody
    • FCC1 antibody
    • hMSH2 antibody
    • HNPCC 1 antibody
    • HNPCC antibody
    • HNPCC1 antibody
    • LCFS2 antibody
    • MSH 2 antibody
    • Msh2 antibody
    • MSH2_HUMAN antibody
    • MutS homolog 2 antibody
    • MutS homolog 2 colon cancer nonpolyposis type 1 antibody
    • MutS protein homolog 2 antibody
    see all

Anti-MSH2 antibody - ChIP Grade 画像

  • Anti-MSH2 antibody - ChIP Grade (ab16833) at 1/500 dilution + Human Glioblastoma whole cell lysate

    Secondary
    HRP-conjugated Goat anti-Rabbit at 1/7500 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 100 kDa


    Exposure time : 30 minutes

    This image is courtesy of an anonymous Abreview

    See Abreview

  • IHC image of ab16833 staining in human seminoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab16833, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

Anti-MSH2 antibody - ChIP Grade (ab16833) 使用論文

This product has been referenced in:
  • Sousa MM  et al. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. PLoS One 8:e55493 (2013). WB ; Human . Read more (PubMed: 23405159) »
  • Gannon AM  et al. MutSß and histone deacetylase complexes promote expansions of trinucleotide repeats in human cells. Nucleic Acids Res 40:10324-33 (2012). WB, ChIP ; Human . Read more (PubMed: 22941650) »

See all 4 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: 25°C
Antigen retrieval step Heat mediated
Sample Human Tissue sections (endometrial cancer)
Specification endometrial cancer
Permeabilization No
Fixative Formaldehyde
Username

Abcam user community

Verified customer

投稿 Jul 23 2013

Thank you for confirming these details and for your cooperation.
A.is on holidays, so I will deal with your request.
The details provided enable us to closely monitor the quality of our products.
I am sorry this product did not perform a...

Read More

Thank you for contacting us.

I am assuming the species customer of tissue sections is human - antibodeis are asfollows;

The best anti annexin a1 antibody is ab47661;http://www.abcam.com/Annexin-A1-antibody-ab47661.html

anti I...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (Glioblastoma cell line)
Loading amount 20 µg
Specification Glioblastoma cell line
Treatment Lysis fuffer (urea/thiourea)
Gel Running Conditions Reduced Denaturing (4-20 %)
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 1% · Temperature: RT°C
Username

Abcam user community

Verified customer

投稿 Jan 08 2010

Thank you for your enquiry. This antibody was raised against full length recombinant MSH2 protein. Since it is a polyclonal antibody, it will consist of a mixed population which will recognise different epitopes across the entire protein. I hope...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"